Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers [1][3] - The company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [2] Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA, found in 14% to 17% of cancer patients [3] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, an oral selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral selective inhibitor of ribonucleotide reductase (RNR) [3] - These candidates are currently being evaluated in the phase 1/2 POTENTIATE clinical trial for patients with oncogene amplified cancers [3] - Additionally, Boundless Bio is conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable selective Kinesin degrader [3] - The company is headquartered in San Diego, CA [3]

Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies for oncogene amplified cancers through the study of extrachromosomal DNA (ecDNA) [2] Group 1: Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA observed in 14% to 17% of cancer patients [2] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor [2] - Boundless Bio is conducting a phase 1/2 clinical trial named POTENTIATE to evaluate the combination of BBI-355 and BBI-825 in patients with oncogene amplified cancers [2] Group 2: Upcoming Presentation - Boundless Bio will present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 22-26, 2025, in Boston, MA [1] - The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355 targeting unique dependencies of oncogene amplified cancers [1] - The poster session is scheduled for October 23, 2025, from 12:30 PM to 4:00 PM ET, located at Level 2, Exhibit Hall D [1]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers, addressing a significant unmet medical need [3] - The company is investigating extrachromosomal DNA (ecDNA), which is implicated in oncogene amplification in 14% to 17% of cancer patients [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3] - The next therapeutic candidate, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) and has been evaluated in a Phase 1/2 clinical trial for cancer patients with resistance gene amplifications [3] - The company is also conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable Kinesin degrader [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. ET [1][2]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers by targeting extrachromosomal DNA (ecDNA), which is implicated in 14 to 17% of cancer cases [3]. - The company is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3]. - Boundless Bio utilizes its Spyglass platform for additional programs that are in preclinical development and discovery [3]. Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at Leerink's Global Healthcare Conference on March 12, 2025, at 11:20 a.m. ET in Miami, FL [2]. - A live and archived webcast of the session will be available on Boundless Bio's website under the "Events & Presentations" section [2].